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Abstract
The Human Papillomavirus (HPV) Prevention and Control Board is an independent multidisciplinary board of
international experts that disseminates relevant information on HPV to a broad array of stakeholders and provides
guidance on strategic, technical and policy issues in the implementation of HPV control programs. In response to
drastic drop of vaccine coverage following the adverse event crisis in Carmen del Bolivar, Colombia, the HPV
Prevention and Control Board in collaboration with the Colombian National Cancer Institute and Colombian League
Against Cancer convened a meeting in Bogota, Columbia (November 2018). The goal of the meeting was to bring
together national and international group of experts to report the disease burden, epidemiology and surveillance of
HPV and HPV-related cancers, to discuss the successes and especially the challenges of HPV vaccination and
screening in Colombia, as well as the lessons learnt from neighbouring countries. The meeting provided a platform
to confer various stakeholder’s perspectives, including the role of the Colombian healthcare system and to catalyse
various parts of the public health community in Colombia into effective action. The conclusion of the meeting
included following suggestions to strengthen HPV prevention and control: 1) Re-introducing school-based vaccine
programs, 2) Integrating primary and secondary prevention programs, 3) Developing an innovative crisis
communication plan targeting healthcare workers, teachers and general population, 4) Building trust through
efficient and timely communication, 5) Building strong relationship with media to ensure a stable vaccination
campaign support, and 6) Promoting empathy among healthcare professionals towards patients to build trust and
communicate effectively.
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Introduction
The HPV Prevention and Control Board (www.
hpvboard.org) [1] is an international independent multi-
disciplinary board created in 2015 by the prominent ex-
perts in the field. The HPV Board aims at being the
important catalyst to multiply and disseminate relevant
information on HPV prevention and control to a broad
array of stakeholders. The board is comprised of a prom-
inent group of experts serving as advisors to the board
who provide evidence based reflection and guidance on
strategic, technical and policy issues that occur as we
forward in the implementation of HPV control pro-
grams. It contributes to control of HPV infection, pre-
vention and screening strategies of HPV related cancers
by organizing two meetings per year; 1) a technical
meeting covering topics such as vaccine characteristics,
vaccine safety, screening technologies and landscape,
treatment strategies, dealing with anti-vaccine messages,
and 2) a country meeting covering SWOT analysis of a
country or region. The HPV Board convened its sixth
meeting in Bogota, Colombia on November 15–16, 2018
to address drastic drop of vaccine coverage due to re-
ported adverse events following HPV vaccination in a
school-based programme in Carmen del Bolivar,
Colombia. The crisis resulted in vaccine uptake among
eligible girls declined to 14% for the first dose and 5%
for the complete course, down from 98 and 88%, re-
spectively, in 2012 [2]. The objectives of the meeting
were: understanding epidemiology, burden of disease
and surveillance related to HPV and HPV related can-
cers in Colombia; discussing successes, topical issues
and challenges related to HPV vaccination and screening
particular to Colombia; and with a focus on the current
crisis situation reviewing country examples from Latin
America to learn from their successes and challenges;
gaining insight into various stakeholder perspectives;
and propose recommendations for the way forward; and
advise other countries how to deal with these crises
when they occur. Germane to the discussion were pre-
sentations on the Colombian health care system, to shed
light on possible roles that it may have in averting vac-
cine confidence issues. An important challenge for
Colombia is to recover the HPV vaccination coverage to
levels before the Carmen de Bolivar crisis in 2014. Inter-
national and local experts discussed all aspects that
could enhance HPV vaccine uptake. However, this also
provided an opportunity to discuss optimization of cer-
vical cancer screening efforts in Colombia. This report
summarizes the discussions and lessons learned from
the participants.
The healthcare system in Colombia
Colombia is divided into 32 departments and one capital
district, each with its own governor.
It has a population of approximately 45.5 million in-
habitants, unevenly dispersed over the country. This is
directly related to the geographical diversity of the coun-
try, including a mountain range, coastal regions, plains
and the Amazon rainforest. Together, the lowlands com-
prise over 50% of the territory, but contain approxi-
mately 5% of the population. Moreover, 76% of the
population live in urban areas. The age composition of
Colombia is approximately 23% aged < 18, 68% aged 18–
65 and 9% > 65 years. The life expectancy is 76 years and
is slightly higher in females than in males. In 2017, the
National Administrative Department of Statistics re-
ported that 27% of the population was living below the
poverty line, of which 7% of the population lived in ex-
treme poverty.
Health insurance comes in two forms: a subsidized
system for people with low income, and a contributing
system for those who have a job and make monthly pay-
ments to the system. An estimated 97% of the popula-
tion is covered by health insurance that provides broad
benefits for all ages and all incomes. Nationally, the cost
of healthcare is between 6 and 8% of the gross domestic
product. It is a very complex healthcare system that has
three main actors: the territories or political entities
(municipalities and departments), the Entidades Promo-
toras de Salud (EPS) are the insurance companies that
can be public or private and the Instituciones Presta-
dores de Salud (IPS) are the healthcare providers (hospi-
tals and clinics) which mainly are privately owned. Each
person can choose his/her EPS. The Ministry of Health
coordinates the actions of these sectors.
The major problems in the Colombian healthcare sys-
tem are: over-consumption, too many procedures; frag-
mentation due to an abundance of private insurers, lack
of coordination between the basic health care providers
and the complementary ones; lack of third-level care;
high cost of administration; lack of qualified personnel;
inequality in care; and systematic focus on treatment of
disease rather than disease prevention [3–5].
A new health system model has been proposed that re-
thinks the health system from one based on performance
and payment of services to a model around people; it
reorients the health system towards holistic health care,
which does not focus on disease but promotes health
and well-being of people at the level of primary and
community care, as well as at levels of greater complex-
ity. This model proposes the creation of health networks
and the production of knowledge in health and well-
being, whose positive results have been demonstrated in
Colombia by Compensar EPS [6]. This insurer
contracted hospitals, clinics, primary care teams and
other health-related providers to deliver the services
needed by the population it had committed to serve. To-
gether, they developed a model to integrate their
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activities and align their incentives, ensuring that every
person had a family physician, which is supported by
community-based providers, with access to a good hos-
pital environment and home care, while being enabled
by a leading-edge information system.
Epidemiology of HPV and cervical cancer in
Colombia
The role of Colombia in HPV epidemiology research
Colombia has a rich history of research on HPV epi-
demiology and public health, mostly performed by the
International Agency for Research on Cancer (IARC,
Lyon, France), in collaboration with the Vale University,
the Colombian Cancer Institute and the Catalan Insti-
tute of Oncology (ICO). This includes the first
population-based case-control study that established the
causal association between HPV and cervical cancer,
performed in Cali and in Spain including 400 cervical
cancer cases and 450 controls [7], followed by a larger
study conducted in 11 countries that included 2500 cer-
vical cancer cases and 2500 controls [8], This study pro-
posed an epidemiological classification of HPV types, in
high-risk, intermediate-risk and low-risk types and esti-
mated that HPV16 and 18 were responsible for 70% of
cervical cancers and HPV 31, 33, 45 52 and 58 for an
additional 20%. Colombia also participated in one of the
first multi-site studies investigating the male role in
HPV transmission and the risk of cervical cancer. This
study showed that penile HPV prevalence was high in
both husbands of women with cervical cancer and
women from control group, in all countries except Spain
where husbands of women with cervical cancer had a
higher penile HPV prevalence than husbands of women
from control group. Furthermore, the protective effect of
circumcision was shown in circumcised men, HPV
prevalence was much lower in penile swabs [9].
Colombia participated, as one of 22 countries, in the
International Prevalence Survey that established HPV as
necessary cause of cervical cancer [10], and provided
samples from 1800 women for the IARC International
Survey on HPV types in women without cervical cancer
[11]. This study reported an HPV DNA prevalence of
15% in Colombian women aged 15 to 64 years. Colom-
bian samples from cervical cancer, other genital cancers
and Head & Neck (H&N) cancer cases were also in-
cluded in the ICO International Survey on HPV-
associated cancers [12].
Finally, to investigate the natural history of HPV, a co-
hort study was performed in Bogota [13], that followed
approximately 2000 women, aged 15 to 80 years, every 6
months for 10 years. This study showed the prevalence
and incidence of type-specific infection with HPV in
women with normal cytology and women with cervical
neoplasia. The incidence of high-risk types was higher
than that of low-risk types (5.0 vs. 2.0 cases/100 woman-
years), and infections with high-risk types lasted longer,
on average, than infections with low-risk types (14.8 vs.
11.1 months) [13]. All above studies conducted in
Colombia, were a key element in the decision of the Co-
lombian government to introduce the HPV vaccine in
the national immunization program.
Burden of HPV associated cancers in Colombia
In Colombia, cervical cancer is by far the most promin-
ent HPV-associated cancer (Table 1). However, between
1998 and 2014, there was a steady increase in the num-
ber of non-cervical genital cancers, specifically cancer of
the anus, of the vulva and of the penis. This increase
was more prominent in women than in men.
Colombia contributed 1203 specimens to the ICO
International survey on HPV-associated cancers
(Table 2). Based on HPV prevalence studies, disregard-
ing potential cross-protection, vaccination with the 2-
valent or 4-valent vaccine could prevent 68% of cervical
cancers in Colombia, and between 48 and 81% of the
other HPV-associated cancers, whereas the 9-valent vac-
cine could prevent 88% of cervical cancers, and between
85 and 100% of the other HPV-associated cancers. These
results are similar to those published previously, based
on a similar dataset [14]. In H&N cancers, the second
most frequent type of cancer related to HPV infection
among Colombians, there are large differences in HPV
prevalence between sub-sites, with HPV prevalence in
oropharynx (62.5%) being much higher than in other
sites (oral cavity 8.6%; larynx 19%).
Based on the reduction in cervical cancer incidence,
from a high-risk country with incidence rates above 30
per 100,000, Colombia has now become an
intermediate-risk country, with rates about 15 per 100,
000, although still leaving room for improvement. A
similar reduction on mortality rates has been observed
in the last 30 years, especially in middle and high-
income groups and populations with easy access to
Table 1 Burden of HPV-associated cancers in Colombia
Annual number of cervical cancers cases 4661
Annual number of cervical cancer deaths 1986
Crude incidence rates (x/100,000 per year) Male Female
Cervical cancer – 19.3
Anal cancer 0.2–1.3 0.8–1.9
Vulvar cancer – 0.5–1.0
Vaginal cancer – 0.0–0.7
Penile cancer 1.1–2.2 –
Oropharyngeal cancer 0.8 0.3
Source: HPVcentre.net, fact sheet Colombia 2017. The ranges (where provided)
represent the lowest and highest recorded rates in different regions of
the country
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health services. Large geographical differences in the
mortality rates are observed in Colombia, with the high-
est rates in remotes areas with low density of population
and difficult access to health services.
On the other hand, 5 years-survival rates for cervical
cancer have been increasing during the last two decades
in Cali, Colombia, but are still lower (46%) than those
reported from the US (63%) and other developed coun-
tries [15].
Despite the evident decrease in mortality, there is still
ample evidence to aim for improvements in HPV vaccin-
ation and cervical cancer screening. First of all, in view
of the clear inequality in cervical cancer mortality with
higher rates in women from low socio-economic groups
and difficult access to health services, vaccination is a
more certain way to achieve equality. Secondly, vaccin-
ation has the potential to decrease cervical cancer inci-
dence to levels below that which can be reached by
screening alone under the best circumstances. Ideally
both vaccination and screening should be integrated into
a cervical cancer preventive program.
Prevention and control of HPV and HPV-related
cancers in Colombia
The cervical cancer screening program in Colombia
Cervical cancer screening was introduced in the 60’s and
was implemented by two NGOs: the Colombian League
against Cancer and Profamilia; however, due to its non-
organized nature and low participation, this proved to
be non-effective. In the 90’s screening was reintroduced
as a National Program under the coordination of the
National Cancer Institute of Colombia which promoted
the practice of Pap smear outside the maternal program
to reach high risk populations, and in 2000 it was regu-
lated based on governmental Resolution 412, which led
to a decrease in cervical cancer incidence [Fig. 1]. The
reductions in cervical cancer incidence, however, have
not been uniform across the population due to differen-
tial follow-up of an abnormal Papanicolaou (Pap) test
based on women’s health insurance: greater follow-up of
abnormal Papanicolaou test results was found for
women with pay-roll insurance while sub-optimal
follow-up of abnormal results occurred for women
Table 2 Potentially preventable fraction of HPV-associated cancers in Colombia with currently available HPV vaccines
Anatomic Site No. HPV DNA+ HPV DNA+ Bivalent (2-valent) or quadrivalent (4-valent) Vaccines HPVDNA + Nonavalent (9-valent) Vaccine
ANUS 39 94.9% 81.1% 100.0%
CERVIX 841 78.4% 67.5% 87.7%
HEAD & NECK 192 26.0% 80.0% 88.0%
PENIS 54 50.0% 70.4% 85.2%
VAGINA 29 72.4% 47.6% 85.7%
VULVA 48 60% 79% 86%
*Based on HPV+ cases
Source: Hernandez-Suarez G, Muñoz, N et al. unpublished results
Fig. 1 Cervical cancer screening timeline and cervical cancer mortality in Colombia
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without insurance as well as those with subsidized insur-
ance [16]. The difference in follow-up care following ab-
normal cervical screening results has resulted in
differences in mortality due to cervical cancer: women
with pay-roll insurance had lower mortality rates than
women with subsidized or no health insurance. No dif-
ferences were observed between women with subsidized
insurance and those without insurance in any age group,
indicating that subsidized insurance did not provide pro-
tection against cervical cancer mortality compared to no
insurance [17, 18].
A new Resolution, number 3280, is in progress, intro-
ducing cytology from 25 to 30 years of age, HPV testing
from 30 to 69 years, and screen-and-treat approaches for
areas with low access to health care as defined by the
Ministry of Health. The new resolution is expected to
result in fewer screening visits for women and creates an
established timeframe between colposcopy and treat-
ment of less than 30 days. The new program will be
monitored to see if there is an impact on the number of
women with cervical precancer high-grade squamous
intraepithelial lesions [HSIL], a cytological diagnosis,
cervical intraepithelial neoplasia [CIN]2/3, a histological
diagnosis, or adenocarcinoma in situ. Shortcomings of
the program seem to be lack of clear stewardship with
no collaborative plan between territories and insurers,
lack of organized quality assurance, and unjustified risk
of screening adolescents as allowed in the new regula-
tion, for whom detection of transient HPV infections
may lead to unnecessary treatment.
The HPV vaccination program in Colombia
In Colombia, HPV vaccines were authorized before na-
tional policy recommendations; within the context of the
decentralized decision-making process, HPV vaccination
activities were driven by pressure from local political ac-
tors [19]. Parents’ acceptability of vaccination in
Colombia varied according to socio-cultural context; in
some regions preventing a sexually transmitted infection
amongst parents of very young girls (< 12 years) hamper
their acceptability [20].
Introduction of the HPV vaccine into national
immunization program was prepared in close cooper-
ation with Colombian scientific societies. In 2008, a
cost-effectiveness study was performed [21], which led
to the introduction of the HPV vaccine into the national
immunization plan in August 2012, at the same time as
the hepatitis A vaccine. The 4-valent vaccine was
chosen, because of the added protection against genital
warts due to the inclusion of HPV 6/11. The target
population was girls in 4th grade of primary school and
aged 9 years and older, to be vaccinated in a school-
based system. Soon after vaccine introduction, in 2013
the vaccination schedule was changed from 3 doses at 0,
2 and 6months to 0, 6, and 60 months in the hope that
the dose at 60 months would not have to be given, as
initial studies began to show the benefits of a two-dose
schedule. The reduction in number of doses allowed a
catch-up program, aimed at girls between 9 and 17 years
of age, resulting in a 1st dose coverage of 94.8% and a
2nd dose coverage of 76.6%. This catch-up program was
implemented only in 2013.
In 2014, and thereafter, the target population was
again girls in 4th degree of primary school older than 9
years of age. In June 2014, reports of adverse symptoms
(headaches, paresthesia, and back pain) were received
from girls residing in Carmen de Bolivar who received
the 2nd dose of the HPV vaccine. After a few days, simi-
lar symptoms were reported from more than 600 girls.
This news was in the headlines for 2 weeks. Despite
studies showing that there was no correlation with vac-
cination, a big drop in coverage ensued, to 60% in 2015
and to 6% in 2016. In addition, the National Academy of
Medicine recommended that a screening for auto-
immune diseases be performed before the administration
of the HPV vaccine. Due to these events, school-based
vaccine programs were discontinued.
To increase vaccine confidence, a media campaign was
initiated, involving high-level medical figures, which re-
sulted in a slight increase (17.6%) in vaccine coverage in
2018.
In April 2018, the Ministry of Health decided to
change the HPV vaccination scheme to two doses (0 and
6months), for all immunocompetent girls between 9
and 18 years of age. For optimal impact of the vaccin-
ation program, the following has been considered neces-
sary: 1) acceptance of the vaccine by the adolescents/
teenagers and their parents; 2) appropriate knowledge
and understanding of the vaccine by healthcare workers;
3) correct management of information about vaccine
safety; and 4) immediate response to rumors about the
vaccine [22–23].
Vaccine surveillance in Colombia
In 2008 the Colombian National Institute of Health and
the Colombian Institute of Surveillance of Drugs and
Food (INVIMA) started the Eventos Supuestamente
Atribuibles a la Vacunación o Inmunización (ESAVI)
program to perform the surveillance for potential vac-
cine adverse events in Colombia. This surveillance sys-
tem is one of the strongest in America, it is nominal or
individual and it is based on weekly reports from nearly
5200 health institutions, representing 1117 municipal-
ities [22]. In addition, it also includes information from
6300 other sources. All events are reported in which a
patient presents with any disorder, syndrome, sign or
symptom that might be related to the administration of
a vaccine, with a maximum delay of 4 days. This includes
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injection site abscesses; events that require
hospitalization; events that cause disabilities; death oc-
curring within 4 weeks after the administration of a vac-
cine, and potentially related to vaccination; events that
are above the expected incidence in the population; and
any rumor about the safety of a vaccine that is generated
in the media. These events (or rumors) are investigated
and classified as: 1) a case related to the vaccine - the
event has been described as a reaction to the vaccine
due to its components, fulfilling the causality criteria; 2)
a programmatic error – a case in which it is possible to
identify a failure in the application, storage and distribu-
tion of the vaccine; 3) a coincidental case – an event that
occurred at the time of administration of the vaccine,
without a clear relationship to the vaccination; 4) incon-
clusive event - an event in which not all the necessary
information is available to establish if the event was
caused by the vaccine.
For the HPV vaccine, the Carmen de Bolivar incident
resulted in 240 adverse events (AEs) per 100,000 doses
in 2014 and thereafter the reported rate of adverse
events decreased gradually, to a level similar to other
vaccines, 7–8 events per 100,000 doses. From 2012 to
2018, only one severe AE was reported: a case of compli-
cated urticaria, in which case the subject was hospital-
ized. All other cases were considered as mild and/or not
related to the HPV vaccine.
Potential immune-mediated disorders
Surveillance is performed worldwide in all countries that
have introduced HPV vaccination.
As vaccinations are common, even a small increased
risk of multiple sclerosis (MS) or other acquired central
nervous system demyelinating syndromes (CNS ADS)
could have a significant effect on public health. How-
ever, no long-term association of the HPV vaccine with
MS or any other CNS ADS was found, arguing against a
causal association [23, 24]. Similarly, in a nationwide
register-based open cohort study in Sweden, HPV vac-
cination was not associated with an increased incidence
of new-onset autoimmune disease in girls and women
with pre-existing autoimmune disease [25], which is
relevant for the Colombian situation, as currently, test-
ing for autoimmune diseases is advised before vaccin-
ation. Looking for incident hospital diagnosed
autoimmune, neurological, and venous thromboembolic
events (53 different outcomes) up to 180 days after each
HPV vaccine dose, no evidence supporting associations
between exposure to HPV vaccine and these events was
found in Denmark and Sweden [24]. Although associa-
tions for three autoimmune events were initially ob-
served, on further assessment these were weak and not
temporally related to vaccine exposure. In contrast, in-
verse associations were found with epilepsy (rate ratio
0.66, 95% confidence interval 0.54 to 0.80) and paralysis
(0.56, 0.35 to 0.90) [26].
Findings from a qualitative review of 14 safety studies
on CNS ADS, MS, and optic neuritis strongly supported
the absence of an association between HPV vaccines and
central demyelination [27]. Owing to limited data on
Guillain-Barré syndrome (GBS), no meta-analysis could
be performed for this outcome. Data from French nation-
wide databases suggested that the incidence of GBS was
increased among vaccinated girls (incidence rate of 1.4
among vaccinated [20 cases] versus 0.4 per 100,000 person
years among unvaccinated [23 cases]; adjusted hazard ra-
tio: 3.78 [1.79–7.98]). Under the hypothesis of a causal re-
lationship, this would result in 1–2 GBS cases attributable
to HPV vaccine per 100,000 girls vaccinated [28]. How-
ever, based on Hospital Episode Statistics (HES), no evi-
dence of an increased risk of GBS was found following
HPV vaccination in England. Based on the upper end of
the 95% CI for the relative incidence and the number of
HPV vaccine doses given in England, the data can exclude
a risk of about 1 per million doses [29].
Similarly, for postural orthostatic tachycardia syn-
drome (POTS) the Vaccine Adverse Event Reporting
System (VAERS) database for reports of POTS following
HPV vaccination 2006 to 2015. Among 40,735 VAERS
reports, 29 POTS reports that fully met diagnostic cri-
teria were identified: approximately one POTS case per
6.5 million HPV vaccine doses. No unusual or unex-
pected reporting patterns was detected that would sug-
gest a safety problem [30]. These combined data led the
Global Advisory Committee on Vaccine Safety of the
World Health Organization (GACVS) to conclude that
since licensure of HPV vaccines, GACVS has found no
new adverse events of concern based on many very large,
high quality studies and therefore GACVS considers the
HPV vaccines to be extremely safe [31]. Nevertheless, in
Japan, HPV vaccines became part of the national
immunization program in April 2013. In response to
media coverage regarding possible adverse events, the
Japanese government suspended proactive recommenda-
tion of its use in June 2013. In total, 2584 adverse events
were reported, out of a total of 8.9 million HPV vaccine
doses (0.03% of total doses) given to 3.38 million persons
(0.08% of total persons) [32]. Of those reporting adverse
events, approximately 90% complete recovered, 186 per-
sons still received medical care, 3 died (due to suicide,
neoplasm and cardiac disease) and 2 people had long-
term health effects. At the same time, the mortality rate
from cervical cancer in Japan increased by 3.4% from
1995 to 2005 and is expected to increase by 5.9% from
2005 to 2015, in particular among women aged 15–44
years [33].
In conclusion, the issues of safety as well as the need
for the HPV vaccine must be addressed with healthcare
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workers, adolescents and parents. HPV vaccines were
developed to prevent cancer and save lives. To this ef-
fect, it may help to train (future) healthcare workers
(HCWs) to provide a strong recommendation of the
vaccine.
Monitoring effectiveness of HPV vaccination in Colombia
To evaluate the effectiveness of the HPV vaccination
program, type-specific HPV prevalence was compared
between 1451 vaccinated and 951 non-vaccinated
women aged 18–25 years old, from a single Colombian
city, 5 years after vaccination [34]. Significant reductions
were observed in all vaccine types, with a reduction of
74% for HPV 6, 100% for HPV 11, 73% for HPV 16 and
55% for HPV 18. Furthermore, limited reductions in
HPV types 31 and 45 were observed in vaccinated versus
unvaccinated women (although not statistically signifi-
cant), suggesting that the vaccine might provide some
degree of cross-protection against non-vaccine high-risk
HPV types. Results have shown that optimal benefit of
vaccination was obtained when women were vaccinated
with a complete vaccination schedule, before sexual
debut.
Successes and challenges in other countries/
regions
Brazil
Brazil is a large country with great geographical differ-
ences between regions. The target population for HPV
vaccination comprises 17 million boys and girls, aged be-
tween 9 and 14 years. Cervical cancer is the 3rd most
frequent cancer among women, with an incidence of
15.4 cases /100,000, and 5000 deaths per year.
From 2014, HPV vaccination was introduced in a
scaled-up fashion, first targeting 11–13-year-old girls, in
a 3-dose schedule, followed in 2015 by vaccination of
males and females living with Acquired immunodefi-
ciency syndrome (AIDS). In 2016, the target age for girls
was expanded to 9–14-year-olds and beginning in 2017,
boys were targeted between the ages of 11–14 years, as
well as males and females, aged between 15 and 26 years,
with weakened immune systems. Since the start of the
vaccination program, 37.5 million doses of vaccine have
been given.
To establish a baseline for evaluation of the effective-
ness of HPV vaccination in Brazil, the POP-Brazil study
[35] is investigating HPV prevalence and genotypes, in
sexually-active men (n = 1774) and women (n = 5812),
aged 16 to 25 years. 35% of participants had a high-risk
infection and 31% had an infection with more than one
HPV type. In September 2014, 80 girls presented with
symptoms (paresis, numbness, temporary legs paralysis,
similar to those seen in Colombia. All were hospitalized
but recovered spontaneously. The authorities judged the
symptoms to be related to immunization anxiety. Never-
theless, this situation had a negative impact on vaccine
coverage. In total, between 2014 and 2018, 163 serious
AEs were reported, with an average incidence of 0.67
cases per 100,000 doses.
Several steps were considered important to improve
vaccination coverage in Brazil, including: improving the
interface between health and education sectors, espe-
cially the health in school program; introducing/enfor-
cing an immunization requirement for school entry;
improving the quality of information on, and evaluation
of, the vaccine; instituting partnership with scientific so-
cieties and civil society; progress in the operation of the
National Immunization Program Information System
throughout the country.
Peru
As one of the countries in the Merck-PATH study, the
HPV vaccine was introduced in Peru in 2008. This study
showed that school-based vaccination leads to the high-
est vaccine coverage. Peruvian parents were very positive
about vaccines, believing strongly in the value of vac-
cines. Furthermore, vaccines were provided for free and
recommended by the Minister of Health. The main rea-
son for not being vaccinated was absence of school at
the day of vaccination; neither fear of early sexual debut
nor adverse events were mentioned as reasons for not
being vaccinated.
Although the Peruvian president announced that HPV
vaccination would start in 2008, it was only in 2011 that
a ministerial resolution was released. Defining age of
vaccination at 10 years, 280,000 girls were going to be
vaccinated with the bivalent vaccine. However, the vac-
cination program was not budgeted, and no vaccination
database was available. Therefore, active immunization
at schools, as part of the initial strategy, was stopped. In
2015, the 4-valent vaccine was bought with the help of
UNICEF and the Pan American Health Organization.
This led to an increase in first dose vaccine coverage to
77%, similar to what was achieved in 2011, whereas 3-
dose coverage reached 66%.
Several measures were taken to increase coverage of
4-valent human papilloma virus (4vHPV) vaccine: the
vaccination scheme was changed from three to two
doses; a training program for health care workers
about HPV vaccination was initiated; training was or-
ganized for directors of education and directors of
schools in 24 regions on HPV and HPV vaccine;
strategies were developed to involve parents and make
it possible to obtain parental consent through the
Internet; and a communication campaign was started,
involving politicians and the media, and having a TV
actress as the face of the campaign. Finally, a contest
was held between 24 regions, to see which region was
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going to be the champion for a new generation of
women without cervical cancer.
Future points of attention to further improve vaccin-
ation coverage are underway including development of
an electronic vaccination card; facilitating electronic ac-
cess for mothers to obtain their children’s vaccination
records; changing vaccination informed consent from
opt-in to opt-out; and consideration of catch-up,
gender-neutral, and 1-dose vaccination strategies. Fur-
thermore, measurement of vaccine impact is being
considered.
Panama
In 2008, Panama began a school-based HPV vaccine
program, administering 2-valent HPV (2vHPV) vaccine,
given at the age of 10 years according to a 3-dose sched-
ule (0, 1, and 6 months). Beginning in 2015, the 4-valent
HPV vaccine was used instead of 2-valent HPV. If the
mother took her daughter for vaccination, she would be
offered a Pap test herself. That same year, catch-up vac-
cination was offered to girls aged 16–17 years, in higher-
risk regions, using the remaining 2vHPV doses. In 2016,
the 4vHPV was also offered to boys from 10 years of age.
In 2017, the vaccine coverage was 69%, which was rela-
tively low, due to lack of 4-valent HPV vaccine stock,
not due to AEs and its consequences. The vaccination
crisis in Colombia was covered in the news, but there
was a quick response in Panama to any anti-vaccine
movement, with journalists involved. The Panama ex-
perience demonstrated that a political decision is needed
to effectively set up HPV vaccination.
Ireland
In Ireland, a school-based HPV vaccination began in
2010 targeting 12–13-year-old girls (approximately 30,
000 per year). In the first 5 years, vaccine coverage was
very high, but in 2015 there was a decline in coverage,
followed by a massive drop in 2016. Some parents raised
major concerns about the vaccine. They were active on
social media as well as TV. In response to this, the
Health Service Executive (HSE) Ireland developed a
website: www.hpv.ie [36], with information on HPV and
the vaccine, and had the website accredited by the
WHO.
Furthermore, the HPV Alliance was established in Au-
gust 2017, which now has 37 member institutions, in-
cluding healthcare workers as well as women’s and
children’s groups, all promoting the vaccine. Fact sheets
were prepared, for schools, general practitioners and
parents. HSE took up social media listening, to be aware
of the rumors going on. In response to the rumors, HSE
became active on social media, including twitter, using
the hashtag #protectourfuture. In all of this, the Health
minister was very supportive. And as a positive outcome,
vaccine coverage increased from 50 to 65%, which is still
lower than before the crisis, but going in the right
direction.
Achievements and challenges in Colombia
Nariño region
This region, along the border of Ecuador, has the highest
vaccine coverage in Colombia. Where it aimed for a 17%
increase, it managed to accomplish an increase to 47%.
This success was due to a number of actions: audits of
healthcare workers, including education on HPV vaccin-
ation, both in public and private IPS; actively going out
to rural areas with low access to healthcare to provide
vaccinations; organizing peer-to-peer discussions on
HPV vaccination in schools; using conventional and
non-conventional media, including local radio stations
to increase awareness; as well as, allocating a specific
nurse for follow-up of women with abnormal Pap smear
results, to guarantee treatment when a lesion was found.
Carmen de bolivar
In 2014, before the crisis, vaccine coverage was 100% in
4198 girls. However, after the 2nd dose, the first cases
appeared. A few days later, more than 600 girls started
to have the same symptoms (headaches, paresthesia,
back pain). Many hypotheses have been formulated to
explain these symptoms, but once vaccination was raised
as option, there was little attention for other potential
explanations. In fact, the advocate leading the anti-
vaccine movement approached the doctor in charge of
two girls who were being attended at the hospital, with
the request to change the diagnosis to syncope induced
by the HPV vaccine.
An independent study carried out by the National In-
stitute of Colombia ruled out a direct relation to the vac-
cine, but this led to much abuse towards spokespeople
of the vaccination program, as it was interpreted as a
callous denial of the symptoms of the girls.
Currently, 4 years later, everything has calmed down.
Sixty-five girls of the group with symptoms are still be-
ing followed closely, but they have not had further crises.
In order to be able to provide the best possible care for
these girls, a mobile unit is being used to reach those
girls in remote areas, who have limited access to health-
care. Furthermore, meetings with the parents have been
organized.
Manizales
In this region, 98% of the population lives in urban
areas, and the population has a high level of education.
To identify barriers and facilitators for HPV vaccination,
a population-based survey was performed on girls born
in the years 2003–2005, as well as their parents. Vaccin-
ation status was defined by girls’ report, parental report,
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and the online official vaccine registry. This showed
good concordance between girls’ self-report of vaccin-
ation and official data. Their school was an important
source of information for those girls who were aware of
the vaccine. Importantly, 40–60% (unvaccinated) to 70–
90% (vaccinated) of the girls were aware that the vaccine
prevents cervical cancer and HPV infection, respectively,
and these were strong reason for uptake of the vaccine.
Nevertheless, 40% of the girls that were vaccinated
thought the vaccine may be dangerous and produces
AEs.
The most important barriers for vaccination were rec-
ommendations against vaccination by relatives or
friends, as well as media attention related to AEs in Car-
men de Bolivar or in other countries. Finally, not being
offered vaccination in the school was an important bar-
rier to completion of the vaccine schedule: these girls
started but often did not complete the vaccine series.
SWOT analysis of HPV vaccination in Colombia
Strengths
Extensive knowledge of the epidemiology of HPV is
available in Colombia, due to participation in scientific
studies. Due to these studies, there is appreciation of the
burden of cervical cancer in Colombia and a sense that
country’s scientists played a key role in the development
of the HPV vaccine.
Colombia has almost universal insurance coverage and
an extremely effective immunization program for all vac-
cines. A strong surveillance program is available, which
is necessary to monitor safety of the vaccination
program.
There is strong political support and political will to
continue and expand the HPV vaccination program,
with consensus among different stakeholders on safety
and effectiveness of the vaccine. The HPV vaccination
program is a well-structured program, which, despite
low vaccine coverage, is equitable. The vaccines are af-
fordable at the country-level, and free for those targeted
by the program.
Weaknesses
HPV vaccination in Colombia is hindered by fragmenta-
tion in communication and continues to recover from a
slow reaction to the Carmen de Bolivar crisis. In general,
a communication plan for dealing with crises is lacking
and there is inadequate capacity for communication with
different groups (HCWs, teachers, general population),
leading to a lack of HPV / cervical cancer education of
HCWs, the public and media. Moreover, communica-
tion, especially with the public, is at the wrong level, be-
ing too complex and too scientific.
Following the Carmen de Bolivar crisis, Colombia
abandoned the school-based system for HPV
vaccination, while it has been shown to be the most
effective system to achieve high coverage. Finally,
HPV vaccination and cervical cancer screening have
not been appropriately integrated.
Opportunities
The recent reports on safety of the vaccine provide an
opportunity to bring the vaccine under the attention of
the media and the public in a positive way, aiming to in-
crease vaccine coverage. Furthermore, the adapted E-
learning course on vaccine safety (see below) is an excel-
lent opportunity to educate HCWs on HPV and cervical
cancer. Given the extensive experience from neighboring
countries with the HPV vaccination program, Colombia
can learn from these countries, copying successful strat-
egies and avoiding pitfalls.
Finally, it would be appropriate to try to show sympathy
to those affected by alleged AEs, regardless of whether
these reactions are directly linked to vaccination. This is
likely to increase the respect and appreciation of the pub-
lic for the vaccination program and the HCWs involved.
Threats
The geographical distribution of the Colombian popula-
tion is a potential threat to the vaccination program: a part
of the population has very limited access to healthcare.
Furthermore, in some parts of the country, the social situ-
ation is (still) unstable. And there is an increasing burden
on the healthcare system due to immigration.
Moreover, frivolous, predatory litigation towards the
HPV vaccination program is likely to harm vaccine
coverage, a problem that is aggravated by the strong ac-
tivism of anti-vaccine groups in Colombia. This anti-
vaccine sentiment may spillover to other countries and
to other vaccine programs in Colombia and may lead to
a higher burden of cervical cancer and other diseases
due to reduced vaccine coverage.
Finally, there is uncertainty about political support in
higher political circles, some opinion leaders are against
the HPV vaccine and the sustainability of the HPV vac-
cination program is not guaranteed.
SWOT analysis of cervical cancer screening in
Colombia
Strengths
Extensive knowledge, and appreciation, of cervical can-
cer is available in Colombia, due to participation in sci-
entific studies. Furthermore, there is strong political will
to eliminate cervical cancer as well as technical leader-
ship, which can be shared with others in the region.
Weaknesses
Colombia does not have a population-based program,
leading to disparities and difficulties in access to
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screening. Furthermore, there is a lack of surveillance
and no program for follow-up of abnormal Pap smears,
which prevents screening from providing any added
value. Finally, changes in the screening program cannot
be introduced due to regulatory stifling.
Opportunities
The new technologies for HPV detection may provide
an opportunity to boost cervical cancer screening in
Colombia. This is also an opportunity to integrate vac-
cination and screening. Furthermore, using different ap-
proaches for different populations (e.g. VIA [visual
inspection after acetic acid], self-sampling), screening
may become more equitable.
New legislation is coming up, integrating different ac-
tions. Finally, an excellent tool has been developed to
train the healthcare workforce. E-oncologia (http://www.
e-oncologia.org) [37] is a virtual oncology training pro-
gram, developed by the Catalan Institute of Oncology
(ICO), with 71 courses and 2300 h of training materials,
in 9 languages. One part of the programme is devoted to
cervical cancer prevention. As trainees can become tu-
tors, a snowball effect in training is envisioned.
The module can be calibrated to local needs, such as
an adapted course for Colombia after the vaccine crisis,
with a focus on the safety of the HPV vaccine. This
course, jointly developed by the ICO and the Colombian
Cancer Institute, is directed towards doctors, nurses
and/or midwives, and in general all health professionals
involved in the primary and secondary prevention of cer-
vical cancer. The chapters have been co-authored by
Spanish and Colombian experts. So far, close to 5000
participants (of whom > 80% are Colombians) have reg-
istered, of whom OVER 70% have completed the course
and completed the final exam successfully.
In fact, the course could possibly be adapted to be
used for non-medical people, such as journalists.
Threats
The geographical distribution of the Colombian popula-
tion is a potential threat to the screening program, a part
of the population has very limited access to healthcare.
Next, in some parts of the country, the social situation is
(still) unstable and, owing to the political crisis in
Venezuela, there is an increasing burden on healthcare
system due to immigration. The cost of screening is very
high and failure to reach an agreement to implement
new techniques may further hamper the screening pro-
gram. Finally, there is no systematic roll-out of informa-
tion to the public.
Colombian stakeholders
In response to the Carmen de Bolivar crisis, the ‘Mesa de
Concertacion’, a roundtable for the elimination of HPV-
related cancer in Colombia, was organized. This roundta-
ble brought together many stakeholders: the Colombian
League against Cancer; Profamilia; universities; scientific
societies (including pediatrics, gynecology, family medi-
cine, oncology); the association of cities; the National
Academy of Medicine; parent associations; the Ministry of
Health; pharmaceutical and diagnostics industry; as well
as foreign organizations, including the American Cancer
Society. Actions following from the roundtable include
education to healthcare providers, regaining confidence in
the vaccine by giving lectures throughout the country, and
reactivation of the school-based system.
The role of media and journalists
Many believe that there is a trend towards sensation
journalism, exacerbated by social media, where everyone
can be a journalist. A bit of background helps to under-
stand the media better: national and regional media
often have very different editorial policies of accepting
topics for dissemination. Furthermore, the way news is
covered depends on more than just the journalist: the in-
clusion of photos; the impact of the layout; the editor,
the choice of title, all aspects that may create a com-
pletely different perception of the news.
Scientists often distrust journalists, but it is necessary to
acknowledge that journalists are actually very powerful
and have a large outreach. Therefore, scientists need to
reach out the journalists, with factual information, keeping
in mind that if journalists receive accessible and clear in-
formation, they are more likely to transmit them to the
public. A relationship with the media is not a one-time af-
fair, it is a permanent relationship, that needs to be nur-
tured. Public health actors must consider journalists their
communication partners.
It is the duty of a journalist to discuss both sides of a
story, but sometimes this results in an incorrect balance; it
may help to point this out, showing the potential negative
consequences (e.g. deaths due to non-vaccination) of pub-
lishing a news item. Well-trained media personnel will
make fewer mistakes. While there are master’s programs
in scientific journalism, science is a very broad topic,
much broader than just health, so specific education for
journalists remains necessary.
Finally, media can be an important factor in discredit-
ing the vaccine. If a good relationship with a journalist is
established, he/she could point out how other journalists
can be reached, to make them allies, avoiding unneces-
sary damage to vaccination programs.
Way forward
After one and a half days of interesting presentations
and lively discussion, it was concluded that there is still
a lot of work to do. Therefore, several action points have
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been formulated that can be pursued to increase vaccin-
ation coverage in Colombia:
 Re-introduce the school-based system for HPV vac-
cination, as it has been shown to be the most effect-
ive system to achieve high coverage.
 Adoption of Resolution 3280 might be a good time to
integrate primary and secondary prevention programs,
as both have the same overall goal: reduction of
cervical cancer. This should be done with a focus on
equity and sustainability of the programs.
 Develop a communication plan for crisis situations
and adequate capacity for communication with
different groups (i.e. HCWs, educators, whole
population). While the e-course is a good tool for
training of HCWs, different ways of educating
teachers and the general population need to be devel-
oped To this respect an alliance is being organized
with the local office of the Open University of Catalo-
nia (UOC), a university with a long tradition in e-
learning educational programs in Spanish language to
support the initiatives of the national cancer institute
 Establish a good and long-lasting relationship with
the media, trying to make them a communications
partner for the vaccination program.
 Bad news is swiftly communicated widely; it is time to
start spreading the good news, at an accessible, non-
technical level, for everyone to understand. Good
news encompasses safety of the vaccine, as shown in a
plethora of studies worldwide, as well as impact of the
vaccine on HPV infections and HPV-associated le-
sions, shown in countries with high vaccination rates
(e.g. Australia), but also in countries with lower vac-
cination rates such as the United States.
 Show empathy, public health officials must show
respect and acknowledge the symptoms of those
affected by them, also if these are not vaccine related.
The plea from families of alleged victims must not be
ignored. Medical Doctors (MDs) and nurses who
sympathize will eventually find an opportunity to
communicate with victims and their families and
better understand their problems and concerns.
Post meeting Progress report
The overall country HPV vaccine coverage rates in-
creased slightly the year following the meeting from 29
to 34% for the first dose and from 9 to 11% for the 2nd
dose. This increase was the result of an increase in a few
regions such as the departments of Antioquia and in
Arauca, where a special project is being implemented. In
other departments, (Nariño and Valle del Cauca), the
rates remain stable or have decreased. (Table 3). To in-
crease coverage of the 2nd dose a delayed second dose
strategy is being discussed; currently it is being adminis-
tered 6 months after the 1st dose.
The Arauca project
After the collapse of the National HPV vaccination pro-
gram following the Carmen de Bolivar event, the Colom-
bian League against Cancer, initiated a project in Arauca
in June 2018 to regain confidence on the HPV vaccine,
in collaboration with the Colombian Ministry of Health,
the American Cancer Society and Johns Hopkins Uni-
versity. Arauca is the Colombian department with one of
the highest mortality rates from cervical cancer (11.4 per
100,000) and one of the lowest HPV vaccination rates. A
new communication strategy was developed from a bio-
psycho-social perspective to educate and sensitize girls
to be vaccinated, the parents of the girls, the teachers,
health care providers and the local mass media on the
benefits and safety of the HPV vaccine. Eighteen months
after starting the project, the coverage rate for the 1st
vaccine dose in Arauca increased from 4.7% in 2017 to
83% in December 2019. Most of the increase in the 1st
dose occurred in the last 6 months of 2019, thus cover-
age of the 2nd dose will be best measured in the first 6
months of 2020. We hope to reproduce this strategy in
other regions of the country.
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Arauca 41% 83% 11% 24%
Antioquia 39% 48% 12% 19%
Nariño 57% 53% 33% 32%
Valle del Cauca 48% 54% 35% 21%
Total Colombia 29% 34% 9% 11%
Source: Information provided by the PAI, MSPS- Ministry of health of Colombia
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